- CSR Summary Not Yet Available
- NCT02951819
- Primary Citation Trial has yet to be published
Trial Information
Generic NameDaratumumabProduct NameDARZALEX®Therapeutic AreaCancers and Other NeoplasmsEnrollment101% Female36%% White81%
Product ClassMonoclonal AntibodySponsor Protocol Number54767414MMY2012Data PartnerJohnson & JohnsonCondition StudiedMultiple MyelomaMean/Median Age (Years)64
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available